Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T22:38:50.841Z.
Calculation as of: 2026-10-06T22:38:50.841Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7871b69def0d47a4b8e1e85f1ab3a71b19ef0e5405565481473c56f3e01c6ed1
PEG RATIO
N/A
60 Degrees Pharmaceuticals, Inc.
Market Cap
$3.90M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | $3.90M | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.65M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.65M | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.21M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.50M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
